Ocean Biomedical (OCEAW) 10-Q2023 Q3 Quarterly report

Filed: 15 Apr 24, 5:27pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: Adaptable, added, aforementioned, arrive, attack, attempt, bifurcation, complaint, Confirmation, de, delinquent, difficulty, disadvantage, EFH, ensuing, equitable, exacerbate, face, falling, fell, fifty, fulfill, furnished, FVO, Immunotherapy, incorrect, Intelligent, interpretation, Israel, John, Jolie, Kahn, mechanism, membership, monetize, noncurrent, platform, reconciliation, refinance, regain, restructure, seize, Similarly, Solak, substance, unreasonable, VIACT, Virion, vulnerability, war

Removed: consent, entirety, incorporated, prospective, qualified

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

OCEAW similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

Certification of Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of The Sarbanes-Oxley Act of 2002

I, Jolie Kahn, Chief Financial Officer of Ocean Biomedical, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

	(i)	The Quarterly Report on Form 10-Q of Ocean Biomedical, Inc. for the period ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, and

	(ii)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

Dated: April 15, 2024

/s/ Jolie Kahn
Jolie Kahn
Chief Financial Officer
(Principal Financial Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.